Scintigraphy

Global Nuclear Imaging Equipment Market 2021-2026: Top Market Players are Agfa HealthCare, Canon, Digirad, General Electric, Mediso and Siemens Healthcare

Retrieved on: 
Tuesday, March 30, 2021

DUBLIN, March 30, 2021 /PRNewswire/ -- The "Global Nuclear Imaging Equipment Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 30, 2021 /PRNewswire/ -- The "Global Nuclear Imaging Equipment Market" report has been added to ResearchAndMarkets.com's offering.
  • The nuclear imaging equipment market is broken down into product types such as SPECT scanners, hybrid PET and planar scintigraphy.
  • The report also includes a discussion of the major players across each regional market for nuclear imaging equipment.
  • It explains the major drivers and regional dynamics of the global market for nuclear imaging equipment and current trends within the industry.

Global Nuclear Imaging Equipment Market Report 2021-2026: SPECT Scanners, Hybrid PET and Planar Scintigraphy - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 25, 2021

The scope of this report is broad and covers various types of products available in the nuclear imaging equipment market and potential application sectors across various industries.

Key Points: 
  • The scope of this report is broad and covers various types of products available in the nuclear imaging equipment market and potential application sectors across various industries.
  • The nuclear imaging equipment market is broken down into product types such as SPECT scanners, hybrid PET and planar scintigraphy.
  • Factors such as the prevalence of chronic diseases and a growing geriatric population, coupled with an increasing demand for PET, SPECT and planar scintigraphy nuclear imaging equipment, are also providing traction to the global market for nuclear imaging equipment.
  • The report also includes a discussion of the major players across each regional market for nuclear imaging equipment.

Nuclear Imaging Equipment Market by Product, Application & End-user - Global Forecasts to 2025

Retrieved on: 
Monday, March 15, 2021

The global nuclear imaging equipment market is projected to reach USD 4,604.9 million by 2025 from an estimated USD 3,803.5 million in 2020, at a CAGR of 3.9% during the forecast period.

Key Points: 
  • The global nuclear imaging equipment market is projected to reach USD 4,604.9 million by 2025 from an estimated USD 3,803.5 million in 2020, at a CAGR of 3.9% during the forecast period.
  • Based on product, the nuclear imaging equipment market is segmented into hybrid PET imaging systems, SPECT imaging systems, and planar scintigraphy imaging systems.
  • Based on application, the nuclear imaging equipment market is segmented into oncology, cardiology, neurology, and other applications.
  • Based on end user, the nuclear imaging equipment market is segmented into hospitals, imaging centers, academic & research centers, and other end users.

Global Nuclear Imaging Equipment Market (2020 to 2025) - Growing Demand for Data Integrated Imaging Systems Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021

The SPECT imaging systems segment to hold the largest market share in 2020.

Key Points: 
  • The SPECT imaging systems segment to hold the largest market share in 2020.
  • Based on product, the nuclear imaging equipment market is segmented into hybrid PET imaging systems, SPECT imaging systems, and planar scintigraphy imaging systems.
  • The SPECT imaging systems segment is further categorized into standalone and hybrid imaging systems.
  • Based on end user, the nuclear imaging equipment market is segmented into hospitals, imaging centers, academic & research centers, and other end users.

Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases

Retrieved on: 
Wednesday, February 17, 2021

The study will evaluate the capsules safety and tolerability in the gastrointestinal (GI) tract of Normal Healthy Volunteers (NHV).

Key Points: 
  • The study will evaluate the capsules safety and tolerability in the gastrointestinal (GI) tract of Normal Healthy Volunteers (NHV).
  • This study will investigate the in vivo behavior of the DDS using the well-established method of scintigraphic characterization.
  • Gamma scintigraphy will be used to validate the DDS GI localization as well as the drug delivery accuracy using a saline solution payload that includes radioisotopes.
  • Verifying the safety and tolerability of this drug delivery system will allow us to advance this technology to potentially provide a noninvasive, oral solution for safe and effective treatment of this and other GI diseases.

NorthStar Medical Technologies Expands Portfolio with Exclusive, Worldwide Licensing of Investigational Fibrin-targeted Cardiac Diagnostic Imaging Agent

Retrieved on: 
Tuesday, March 3, 2020

Under the agreement, NorthStar has licensed exclusive rights to a fibrin-targeted diagnostic imaging agent for cardiac imaging.

Key Points: 
  • Under the agreement, NorthStar has licensed exclusive rights to a fibrin-targeted diagnostic imaging agent for cardiac imaging.
  • FibroScint is a unique diagnostic agent and an ideal addition to our portfolio which complements the commercially available RadioGenix System (technetium Tc 99m generator).
  • NorthStar Medical Radioisotopes is a global innovator in the production and distribution of radioisotopes used for medical imaging and therapeutic purposes.
  • Founded in 2006 and based in Beloit, Wis., NorthStar Medical Technologies is the parent organization of several wholly-owned subsidiaries, including NorthStar Medical Radioisotopes, LLC.

Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime®

Retrieved on: 
Monday, January 27, 2020

YARDLEY, Pa., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd , announced today that the company received approval from Health Canada for Drax Exametazine (Kit for the Preparation of Tc99m Exametazime for leukocyte labeling).

Key Points: 
  • YARDLEY, Pa., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd , announced today that the company received approval from Health Canada for Drax Exametazine (Kit for the Preparation of Tc99m Exametazime for leukocyte labeling).
  • Leukocyte labeling scintigraphy is a nuclear medicine imaging procedure that helps physicians localize an intra-abdominal infection and inflammatory bowel disease.
  • We are very pleased that Drax Exametazine is now available to patients in Canada, stated Pramod Yadav, CEO of Jubilant Pharma, Ltd.
  • The Health Canada approval further demonstrates the continued commitment by the Jubilant Radiopharma business to advance the field of nuclear medicine and supports our ongoing mission to improve lives through nuclear medicine, commented Sergio Calvo, President of Jubilant Radiopharmaceuticals Division.

Zecotek Ships Over US$250,000 of LFS Scintillation Crystals and Announces Internal Strategic Review

Retrieved on: 
Monday, September 24, 2018

The Company also announces that the board of directors and the senior management team have initiated a strategic review focused on maximizing shareholder value.

Key Points: 
  • The Company also announces that the board of directors and the senior management team have initiated a strategic review focused on maximizing shareholder value.
  • Zecotek Imaging China, a subsidiary of Zecotek Imaging Systems (Singapore), is commercializing patented LFS scintillation crystals through its new production facility in Shanghai, China.
  • The LFS series of scintillation crystals are known to be uniquely qualified for components in PET medical scanners.
  • Zecotek's LFS series of scintillation crystals are protected in China and jurisdictions around globe by a worldwide patent (including US patent No.

Zecotek Ships Over US$225,000 of LFS Scintillation Crystals

Retrieved on: 
Tuesday, September 11, 2018

Zecotek Imaging China, a subsidiary of Zecotek Imaging Systems (Singapore), is commercializing patented LFS scintillation crystals through its new production facility in Shanghai, China.

Key Points: 
  • Zecotek Imaging China, a subsidiary of Zecotek Imaging Systems (Singapore), is commercializing patented LFS scintillation crystals through its new production facility in Shanghai, China.
  • The LFS series of scintillation crystals are known to be uniquely qualified for components in PET medical scanners.
  • Zecotek's LFS series of scintillation crystals are protected in China and jurisdictions around globe by a worldwide patent (including US patent No.
  • Founded in 2004, Zecotek has three operating divisions: Zecotek Imaging Systems, Zecotek Optronics Systems, and Zecotek Autotronics with labs located in Canada, Korea, Russia, Singapore and U.S.A.

SAMPack 120-D Includes Radiation Compass, Giving First Responders Directionality in Isotope Location

Retrieved on: 
Wednesday, July 25, 2018

The new design includes dual scintillation detectors which deliver unmatched directionality functions.

Key Points: 
  • The new design includes dual scintillation detectors which deliver unmatched directionality functions.
  • The user has easy-to-follow guidance on the whereabouts of nuclear radiation and shortly after the sources are detected, identification can begin.
  • Location and suggested movement are presented in a Radiation Compass, a graphical and universal representation of which direction to move.
  • Founded in 1963, BNC has been a recognized leader in the field of isotope identification and conducts hundreds of short courses on radiation detection and isotope identification for Federal and State agencies.